Buy Vesugen Research Peptide

What is Vesugen?

Vesugen is a synthetic three-amino-acid peptide (Lys-Glu-Asp) from the Russian bioregulator program, designed to target blood-vessel tissue. It is studied in animal research for its effects on the cells that line blood vessels.

• A short synthetic peptide (Lys-Glu-Asp) studied for its effects on blood-vessel tissue
• Part of the Russian organ-targeted bioregulator research program
• Studied for its effects on blood-vessel lining (endothelial) cell signaling
• Investigated in animal research on blood-vessel aging

For research use only. Not approved for human therapeutic use.

Vesugen, also known by its tripeptide designation KED (Lys-Glu-Asp), is a synthetic tripeptide bioregulator with a molecular weight of 390.39 g/mol. Developed at the Saint Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson peptide bioregulator series, Vesugen was designed based on peptide fractions associated with vascular endothelial tissue. Its structure combines a basic lysine residue with two acidic residues (glutamic acid and aspartic acid), and like other Khavinson bioregulators, it is proposed to exert its biological activity through direct interaction with DNA rather than conventional cell surface receptor binding. Produced via solid-phase peptide synthesis, Vesugen is associated with vascular endothelial gene expression and cardiovascular signalling pathways.

Vesugen has been investigated as an organ-specific short peptide bioregulator within the Khavinson framework. Published in vitro studies have documented that the Vesugen tripeptide modulates proliferation- and senescence-associated gene and protein expression in vascular endothelial cells: in dissociated and organotypic endothelial cultures used as models of replicative senescence and of atherosclerosis/restenosis, KED was reported to increase expression of Ki-67, connexin-43 (Cx43), VEGF and SIRT1, to reduce p53, and to normalise endothelin-1 levels [1]. Consistent with the proposed direct-to-DNA mechanism, molecular-docking studies have placed Vesugen within the core promoter region of the MKI67 (Ki-67) gene, binding the minor groove via a CATC sequence motif, alongside observed effects on endothelial cell proliferation in cultures derived from young and old animals [2], making Vesugen a reference compound in preclinical vascular bioregulation research examining endothelial senescence, Ki-67-associated proliferative signalling, and short-peptide/DNA interaction models.

Vesugen is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Kozlov KL, Bolotov II, Linkova NS, Drobintseva AO, Khavinson VK, Dyakonov MM, et al. [Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis]. Adv Gerontol. 2016;29(4):646–50. .PubMed PMID: 285390252Khavinson VK, Tarnovskaia SI, Lin’kova NS, Guton EO, Elashkina EV. [Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging]. Adv Gerontol. 2014;27(1):108–14. .PubMed PMID: 25051766

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →

Vesugen, also known by its tripeptide designation KED (Lys-Glu-Asp), is a synthetic tripeptide bioregulator with a molecular weight of 390.39 g/mol. Developed at the Saint Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson peptide bioregulator series, Vesugen was designed based on peptide fractions associated with vascular endothelial tissue. Its structure combines a basic lysine residue with two acidic residues (glutamic acid and aspartic acid), and like other Khavinson bioregulators, it is proposed to exert its biological activity through direct interaction with DNA rather than conventional cell surface receptor binding. Produced via solid-phase peptide synthesis, Vesugen is associated with vascular endothelial gene expression and cardiovascular signalling pathways.

Vesugen has been investigated as an organ-specific short peptide bioregulator within the Khavinson framework. Published in vitro studies have documented that the Vesugen tripeptide modulates proliferation- and senescence-associated gene and protein expression in vascular endothelial cells: in dissociated and organotypic endothelial cultures used as models of replicative senescence and of atherosclerosis/restenosis, KED was reported to increase expression of Ki-67, connexin-43 (Cx43), VEGF and SIRT1, to reduce p53, and to normalise endothelin-1 levels [1]. Consistent with the proposed direct-to-DNA mechanism, molecular-docking studies have placed Vesugen within the core promoter region of the MKI67 (Ki-67) gene, binding the minor groove via a CATC sequence motif, alongside observed effects on endothelial cell proliferation in cultures derived from young and old animals [2], making Vesugen a reference compound in preclinical vascular bioregulation research examining endothelial senescence, Ki-67-associated proliferative signalling, and short-peptide/DNA interaction models.

Vesugen is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Kozlov KL, Bolotov II, Linkova NS, Drobintseva AO, Khavinson VK, Dyakonov MM, et al. [Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis]. Adv Gerontol. 2016;29(4):646–50. .PubMed PMID: 285390252Khavinson VK, Tarnovskaia SI, Lin’kova NS, Guton EO, Elashkina EV. [Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging]. Adv Gerontol. 2014;27(1):108–14. .PubMed PMID: 25051766

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS NumberN/A (Khavinson bioregulator)Molecular Weight394.38 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKURSC-VESUGEN-5308

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.

Vesugen, also known by its tripeptide designation KED (Lys-Glu-Asp), is a synthetic tripeptide bioregulator with a molecular weight of 390.39 g/mol. Developed at the Saint Petersburg Institute of Bioregulation and Gerontology as part of the Khavinson peptide bioregulator series, Vesugen was designed based on peptide fractions associated with vascular endothelial tissue. Its structure combines a basic lysine residue with two acidic residues (glutamic acid and aspartic acid), and like other Khavinson bioregulators, it is proposed to exert its biological activity through direct interaction with DNA rather than conventional cell surface receptor binding. Produced via solid-phase peptide synthesis, Vesugen is associated with vascular endothelial gene expression and cardiovascular signalling pathways.

Vesugen has been investigated as an organ-specific short peptide bioregulator within the Khavinson framework. Published in vitro studies have documented that the Vesugen tripeptide modulates proliferation- and senescence-associated gene and protein expression in vascular endothelial cells: in dissociated and organotypic endothelial cultures used as models of replicative senescence and of atherosclerosis/restenosis, KED was reported to increase expression of Ki-67, connexin-43 (Cx43), VEGF and SIRT1, to reduce p53, and to normalise endothelin-1 levels [1]. Consistent with the proposed direct-to-DNA mechanism, molecular-docking studies have placed Vesugen within the core promoter region of the MKI67 (Ki-67) gene, binding the minor groove via a CATC sequence motif, alongside observed effects on endothelial cell proliferation in cultures derived from young and old animals [2], making Vesugen a reference compound in preclinical vascular bioregulation research examining endothelial senescence, Ki-67-associated proliferative signalling, and short-peptide/DNA interaction models.

Vesugen is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Kozlov KL, Bolotov II, Linkova NS, Drobintseva AO, Khavinson VK, Dyakonov MM, et al. [Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis]. Adv Gerontol. 2016;29(4):646–50. .PubMed PMID: 285390252Khavinson VK, Tarnovskaia SI, Lin’kova NS, Guton EO, Elashkina EV. [Epigenetic aspects of peptidergic regulation of vascular endothelial cell proliferation during aging]. Adv Gerontol. 2014;27(1):108–14. .PubMed PMID: 25051766

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS NumberN/A (Khavinson bioregulator)Molecular Weight394.38 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKURSC-VESUGEN-5308

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.